Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vermillion, Inc.
Alloy raises $75m in venture funding to further its mission of open-source antibody technology discovery. It also spins out portfolio companies, like ophthalmic-focused Broadwing.
Tempest goes public via a reverse merger with Millendo. Takeda inks its ninth deal of 2021, a discovery pact with BridGene around its chemoproteomics technology.
Lilly Bio-Medicines president Ilya Yuffa oversees newer products in competitive therapeutic areas and drug classes, but additional indications and new therapies within the group’s immunology, pain and neuroscience focus areas will capitalize on the group’s existing commercial expertise.
Private Company Edition: New capital for health care and life science innovations include a fund for royalty deals, additional anti-infective funding, early-stage money and public health-focused cash. Also, Day One reveals a $130m series B venture round and Notch closes an $85m series A round.
- In Vitro Diagnostics
- Other Names / Subsidiaries
- Abiotic Systems
- Ciphergen Biosystems, Inc.
- Aspira Labs